Data licensing and monetization deals have exploded in recent years among research institutions, so understanding the revenue potential clinical data sets hold in a variety of technology arenas, along with knowing how to handle patient data sharing and consent, has become critical for tech transfer, IP, and research professionals.
An informal study conducted by tech transfer professionals has revealed certain trends in managing and licensing data, offering valuable insight into current practices of TTOs across the country, while providing important guidance in addressing the many challenges associated with data licensing.
That’s why we’ve teamed up with two attorneys from Amster, Rothstein and Ebenstein, LLP, as well as a data licensing expert from Owkin, to bring you this practical and timely webinar:
Register today to learn about the “real world answers” provided by tech transfer and legal experts to the challenging question posed by licensing data.
The agenda includes topics such as:
- The different types of data, and what data can be licensed
- Approaches to patient consent
- Exclusivity in licensing and sublicensing
- Factors to consider in pricing data sets
- Payment types and structures
- Who institutions are sharing revenue with under what types of agreements
Meet your program leaders:
Charles R. Macedo
Partner
Amster, Rothstein and Ebenstein, LLP
Charles R. Macedo litigates in all areas of intellectual property law, including patent, trademark and copyright law, with a special emphasis in complex litigation and appellate work. Companies and individuals from a wide range of industries turn to him to develop offensive and defensive strategies for the development and enforcement of their patent and trademark portfolios.
At the Patent Office, Mr. Macedo has supervised and obtained many large patent portfolios, and served as lead counsel in inter partes review proceedings. Mr. Macedo has also been counsel of record or additional counsel on almost 50 party and amicus briefs before the U.S. Supreme Court, the U.S. Court of Appeals for the Federal Circuit, and other courts of appeal and tribunals. Among other important intellectual property cases, Mr. Macedo was counsel of record in multiple briefings at the Federal Circuit and the Supreme Court in U.S. v. Arthrex, at the Supreme Court in American Axle v. Neapco, Return Mail v. U.S. Postal Service, and at the Federal Circuit and PTAB in St. Regis Mohawak Tribes v. Mylan Pharmaceuticals, Inc.
Mr. Macedo is a thought leader and active participant in many leading intellectual property law organizations. He is currently the co-chair of the PTAB Committee at the New York Intellectual Property Board Association, and previously served on the Board of Directors and as Co-Chair of the Amicus Brief Committee for the same organization. He currently serves on the Editorial Board of the prestigious Journal of Intellectual Property Law and Practice (published by Oxford University Press), and previously served on the Editorial Board of the AIPLA QJ. He is also the author of The Corporate Insider’s Guide to U.S. Patent Practice. He has been cited as an authority on intellectual property issues by the Wall Street Journal, Dow Jones, IAM, BNA, Bloomberg, Inside Counsel, Managing Intellectual Property, Technology Transfer Tactics, IP Law 360, JIPLP and other media.
Brian J. Amos, PhD
Partner
Amster, Rothstein and Ebenstein, LLP
Brian J. Amos, PhD, is a former research neuroscientist who represents universities, research institutions and corporations in IP and data protection, including cultivating patent portfolios worldwide, predominantly in the fields of biotechnology, medical therapeutics & devices, AI applied to diagnostics & medical procedures, pharmaceuticals, and lithium ion battery technologies.
He works closely with scientists, in-house counsel, and Technology Transfer Offices to identify and inventory new protectable IP and patentable technologies; protect discoveries through patents; and commercialize intellectual property through licensing and development arrangements with other business entities.
Dr. Amos’ specific areas of patent procurement include artificial intelligence-based technologies, diagnostic technologies, antibodies and fusion proteins, engineered immune therapeutics and targeted therapies, immune checkpoint interventions, recombinant live vaccines, vaccine enhancers, cancer therapies, nucleic acid sequencing technologies, siRNAs, antisense oligonucleotides, nucleic acid-based nanotechnologies, stem cell-based therapies, cardiac treatments, neurological therapies & rehabilitative interventions, EEG-based methods, medical devices, small molecules, pharmaceutical formulations, complete syntheses of natural products, biosensors, and lithium ion batteries & separators.
Dr. Amos has published articles in Nature Biotechnology and Oxford University Press on patent law issues and has been a webinar presenter to tech transfer professionals and other attorneys on subjects such as patentable subject matter in diagnostics, Bayh-Dole Act compliance, and university data policies & protection.
Because Dr. Amos works alongside patent litigators, his approach to patent prosecution is keenly formed by knowledge of how a patent may be challenged. In addition to having broad experience in all aspects of U.S. patent procurement, including ex-parte PTAB appeals, IPR, PGR, reissue, reexamination, and interference practice, he has extensive experience in international prosecution including before the European, Japanese, Chinese, Canadian and Australian patent offices, as well as European opposition practice. He coordinates U.S. and foreign prosecution with the goal of obtaining the most effective and strongest coverage available, with a particular focus on the most lucrative markets.
Dinesh Divakaran, PhD, MBA
Vice President of Partnerships, North America
Owkin Inc.
Owkin, Inc., is a french-american unicorn venture that combines cutting-edge artificial intelligence and biology to advance drug discovery. In his role at Owkin, he leads a team that builds partnerships and collaborations around multi-modal data, AI/ML and federated learning with academic medical centers, healthcare systems and real world data companies across North America. Before joining Owkin, he worked as Vice President of Healthcare Business Development, North America at Sensnye Health plc., a real world data company based out of Oxford, UK.
Prior to working in the biopharma and health tech industry, Dinesh worked in technology transfer for a decade and a half starting with University of South Florida followed by Texas A&M University System, then North Carolina State University and finally Duke University & Health System, where he eventually served as Director, Digital Innovations with Duke Office for Translation and Commercialization. Dinesh also served as an adjunct faculty at both NC State and USF. While working at Duke and NC State, he served as a reviewer/panelist with the SBIR/STTR grant programs at NIH and NSF. Outside of working in technology transfer, Dinesh had a short stint in venture capital as a fellow with the Alumni Ventures Group. He also served on the boards of three health tech startups and two non-profits.
Dinesh currently serves as an Executive in Residence at the Duke Institute for Health Innovation. He had also served on the Forbes Business Development Council, advisory board of NC TECH, innovation committee at HIMSS and high tech committee at LES, USA & Canada.
